The Spectrum of Liver Diseases Related to ABCB4 Gene Mutations: Pathophysiology and Clinical Aspects

ABSTRACT

Class III multidrug resistance P-glycoproteins, Mdr2 in mice and MDR3 in human, are canalicular phospholipid translocators involved in biliary phospholipid (phosphatidylcholine) excretion. The role of an ABCB4 gene defect in liver disease has been initially proven in a subtype of progressive familial intrahepatic cholestasis called PFIC3, a severe pediatric liver disease that may require liver transplantation. Several ABCB4 mutations have been identified in children with PFIC3 and are associated with low level of phospholipids in bile leading to a high biliary cholesterol saturation index. ABCB4 mutations are associated with loss of canalicular MDR3 protein and /or loss of protein function. There is evidence that a biallelic or monoallelic ABCB4 defect causes or predisposes to several human liver diseases (PFIC3, low phospholipid associated cholelithiasis syndrome, intrahepatic cholestasis of pregnancy, drug-induced liver injury, transient neonatal cholestasis, adult biliary fibrosis, or cirrhosis). Most patients with MDR3 deficiency have a favorable outcome with ursodeoxycholic acid (UDCA) therapy, but some PFIC3 patients who do not respond to UDCA treatment still require liver transplantation. The latter should be good candidates for a targeted pharmacologic approach and/or to cell therapy in the future.

KEYWORDS

Multidrug resistance 3 - ABCB4 - progressive familial intrahepatic cholestasis type 3 - cholesterol gallstone - cholestasis of pregnancy - biliary cirrhosis - low phospholipid associated cholelithiasis - transient neonatal cholestasis - drug-induced cholestasis - ursodeoxycholic acid - adult ductopenia

REFERENCES

• 1 Deleuze J F, Jacquemin E, Dubuisson C et al.. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis.  Hepatology. 1996;  23(4) 904-908
• 2 Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis.  Orphanet J Rare Dis. 2009;  4 1 http://www.ojrd.com/content/4/1/1 , [serial online]
• 3 Trauner M, Meier P J, Boyer J L. Molecular pathogenesis of cholestasis.  N Engl J Med. 1998;  339(17) 1217-1227
• 4 Jacquemin E, De Vree J M, Cresteil D et al.. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood.  Gastroenterology. 2001;  120(6) 1448-1458
• 5 Smit J J, Schinkel A H, Oude Elferink R P et al.. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.  Cell. 1993;  75(3) 451-462
• 6 Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases.  Semin Liver Dis. 2001;  21(4) 551-562
• 7 Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes.  Semin Liver Dis. 2007;  27(1) 77-98
• 8 Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene.  Cell. 1994;  77(7) 1071-1081
• 9 Smit J J, Schinkel A H, Mol C A et al.. Tissue distribution of the human MDR3 P-glycoprotein.  Lab Invest. 1994;  71(5) 638-649
• 10 Smith A J, de Vree J ML, Ottenhoff R, Oude Elferink R P, Schinkel A H, Borst P. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (-/-) mice.  Hepatology. 1998;  28(2) 530-536
• 11 Oude Elferink R PJ, Paulusma C C. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein).  Pflugers Arch. 2007;  453(5) 601-610
• 12 Mauad T H, van Nieuwkerk C M, Dingemans K P et al.. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis.  Am J Pathol. 1994;  145(5) 1237-1245
• 13 Van Nieuwkerk C M, Elferink R P, Groen A K et al.. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.  Gastroenterology. 1996;  111(1) 165-171
• 14 Halilbasic E, Fiorotto R, Fickert P et al.. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.  Hepatology. 2009;  49(6) 1972-1981
• 15 Fickert P, Fuchsbichler A, Wagner M et al.. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.  Gastroenterology. 2004;  127(1) 261-274
• 16 Fickert P, Zollner G, Fuchsbichler A et al.. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.  Gastroenterology. 2002;  123(4) 1238-1251
• 17 Pauli-Magnus C, Kerb R, Fattinger K et al.. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis.  Hepatology. 2004;  39(3) 779-791
• 18 Hoekstra H, Porte R J, Tian Y et al.. Bile salt toxicity aggravates cold ischemic injury of bile ducts after liver transplantation in Mdr2+/− mice.  Hepatology. 2006;  43(5) 1022-1031
• 19 Strautnieks S, Lopes A, Underhill J et al.. Critical residues in the multidrug resistance 3 protein gene associated with adult onset of cholangiopathy and intrahepatic cholestasis of pregnancy.  Hepatology. 2002;  36 415A
• 20 Rosmorduc O, Hermelin B, Boelle P Y, Poupon R E, Poupon R, Chazouillères O. ABCB4 gene mutations and primary sclerosing cholangitis.  Gastroenterology. 2004;  126(4) 1220-1222, author reply 1222–1223
• 21 de Vree J ML, Jacquemin E, Sturm E et al.. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis.  Proc Natl Acad Sci U S A. 1998;  95(1) 282-287
• 22 Pauli-Magnus C, Lang T, Meier Y et al.. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy.  Pharmacogenetics. 2004;  14(2) 91-102
• 23 Ganne-Carrié N, Baussan C, Grando V, Gaudelus J, Cresteil D, Jacquemin E. Progressive familial intrahepatic cholestasis type 3 revealed by oral contraceptive pills.  J Hepatol. 2003;  38(5) 693-694
• 24 Lemoine M, Revaux A, Francoz C et al.. Albumin liver dialysis as pregnancy-saving procedure in cholestatic liver disease and intractable pruritus.  World J Gastroenterol. 2008;  14(42) 6572-6574
• 25 Keitel V, Burdelski M, Warskulat U et al.. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis.  Hepatology. 2005;  41(5) 1160-1172
• 26 Müllenbach R, Bennett A, Tetlow N et al.. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy.  Gut. 2005;  54(6) 829-834
• 27 Degiorgio D, Colombo C, Seia M et al.. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3).  Eur J Hum Genet. 2007;  15(12) 1230-1238
• 28 Chen H L, Chang P S, Hsu H C et al.. Progressive familial intrahepatic cholestasis with high γ-glutamyltranspeptidase levels in Taiwanese infants: role of MDR3 gene defect?.  Pediatr Res. 2001;  50(1) 50-55
• 29 Jung C, Driancourt C, Baussan C et al.. Prenatal molecular diagnosis of inherited cholestatic diseases.  J Pediatr Gastroenterol Nutr. 2007;  44(4) 453-458
• 30 Liu C, Aronow B J, Jegga A G et al.. Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis.  Gastroenterology. 2007;  132(1) 119-126
• 31 Morita S Y, Kobayashi A, Takanezawa Y et al.. Bile salt-dependent efflux of cellular phospholipids mediated by ATP binding cassette protein B4.  Hepatology. 2007;  46(1) 188-199
• 32 Lincke C R, Smit J JM, van der Velde-Koerts T, Borst P. Structure of the human MDR3 gene and physical mapping of the human MDR locus.  J Biol Chem. 1991;  266(8) 5303-5310
• 33 Jacquemin E, Hermans D, Myara A et al.. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.  Hepatology. 1997;  25(3) 519-523
• 34 Gupta S, Todd Stravitz R, Pandak W M, Müller M, Reno Vlahcevic Z, Hylemon P B. Regulation of multidrug resistance 2 P-glycoprotein expression by bile salts in rats and in primary cultures of rat hepatocytes.  Hepatology. 2000;  32(2) 341-347
• 35 Hooiveld G JEJ, Vos T A, Scheffer G L et al.. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats.  Gastroenterology. 1999;  117(3) 678-687
• 36 Vos T A, Hooiveld G JEJ, Koning H et al.. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver.  Hepatology. 1998;  28(6) 1637-1644
• 37 Matsumoto T, Miyazaki H, Nakahashi Y et al.. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate.  Hepatol Res. 2004;  30(3) 125-136
• 38 Van Mil S W, Milona A, Dixon P H et al.. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy.  Gastroenterology. 2007;  133(2) 507-516
• 39 Kok T, Bloks V W, Wolters H et al.. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.  Biochem J. 2003;  369(Pt 3) 539-547
• 40 Boyer J L. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?.  Gastroenterology. 2005;  129(2) 735-740
• 41 Trauner M. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?.  Hepatology. 2004;  40(1) 260-263
• 42 Marschall H U, Wagner M, Zollner G et al.. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.  Gastroenterology. 2005;  129(2) 476-485
• 43 Liu Y, Binz J, Numerick M J et al.. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.  J Clin Invest. 2003;  112(11) 1678-1687
• 44 Fiorucci S, Clerici C, Antonelli E et al.. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.  J Pharmacol Exp Ther. 2005;  313(2) 604-612
• 45 Hayashi H, Sugiyama Y. 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps.  Hepatology. 2007;  45(6) 1506-1516
• 46 Delaunay J L, Durand-Schneider A M, Delautier D et al.. A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature.  Hepatology. 2009;  49(4) 1218-1227
• 47 Wilschanski M N, Yahav Y, Yaacov Y et al.. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.  N Engl J Med. 2003;  349(15) 1433-1441
• 48 Ananthanarayanan M. Therapy for hepatocyte transporter trafficking mutations: the time is now.  Hepatology. 2007;  45(6) 1340-1342
• 49 Smith A J, van Helvoort A, van Meer G et al.. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping.  J Biol Chem. 2000;  275(31) 23530-23539
• 50 Lallemand J Y, Stoven V, Annereau J P et al.. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis?.  Lancet. 1997;  350(9079) 711-712
• 51 Altschuler E L. Azithromycin, the multidrug-resistant protein, and cystic fibrosis.  Lancet. 1998;  351(9111) 1286
• 52 Wang R, Chen H L, Liu L, Sheps J A, Phillips M J, Ling V. Compensatory role of P-glycoproteins in knockout mice lacking the bile salt export pump.  Hepatology. 2009;  50(3) 948-956
• 53 Smith A J, van Helvoort A, van Meer G et al.. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping.  J Biol Chem. 2000;  275(31) 23530-23539
• 54 van Helvoort A, Smith A J, Sprong H et al.. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.  Cell. 1996;  87(3) 507-517
• 55 Lamireau T, Bouchard G, Yousef I M et al.. Dietary lecithin protects against cholestatic liver disease in cholic acid-fed Abcb4- deficient mice.  Pediatr Res. 2007;  61(2) 185-190
• 56 De Vree J ML, Ottenhoff R, Bosma P J, Smith A J, Aten J, Oude Elferink R P. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis.  Gastroenterology. 2000;  119(6) 1720-1730
• 57 Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis.  Gastroenterology. 2001;  120(6) 1459-1467
• 58 Rosmorduc O, Hermelin B, Boelle P Y, Parc R, Taboury J, Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults.  Gastroenterology. 2003;  125(2) 452-459
• 59 Kano M, Shoda J, Sumazaki R, Oda K, Nimura Y, Tanaka N. Mutations identified in the human multidrug resistance P-glycoprotein 3 (ABCB4) gene in patients with primary hepatolithiasis.  Hepatol Res. 2004;  29(3) 160-166
• 60 Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene.  Orphanet J Rare Dis. 2007;  2 29 http://www.ojrd.com/content/2/1/29 , [serial online]
• 61 Lucena J F, Herrero J I, Quiroga J et al.. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis.  Gastroenterology. 2003;  124(4) 1037-1042
• 62 Lammert F, Wang D QH, Hillebrandt S et al.. Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis.  Hepatology. 2004;  39(1) 117-128
• 63 Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy.  Lancet. 1999;  353(9148) 210-211
• 64 Holzbach R T, Sivak D A, Braun W E. Familial recurrent intrahepatic cholestasis of pregnancy: a genetic study providing evidence for transmission of a sex-limited, dominant trait.  Gastroenterology. 1983;  85(1) 175-179
• 65 Bacq Y, Sapey T, Bréchot M C, Pierre F, Fignon A, Dubois F. Intrahepatic cholestasis of pregnancy: a French prospective study.  Hepatology. 1997;  26(2) 358-364
• 66 Schneider G, Paus T C, Kullak-Ublick G A et al.. Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy.  Hepatology. 2007;  45(1) 150-158
• 67 Dixon P H, Weerasekera N, Linton K J et al.. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking.  Hum Mol Genet. 2000;  9(8) 1209-1217
• 68 Floreani A, Carderi I, Paternoster D et al.. Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy.  Dig Liver Dis. 2008;  40(5) 366-370
• 69 Eloranta M L, Heiskanen J TM, Hiltunen M J, Mannermaa A J, Punnonen K R, Heinonen S T. Multidrug resistance 3 gene mutation 1712delT and estrogen receptor alpha gene polymorphisms in Finnish women with obstetric cholestasis.  Eur J Obstet Gynecol Reprod Biol. 2002;  104(2) 109-112
• 70 Müllenbach R, Linton K J, Wiltshire S et al.. ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy.  J Med Genet. 2003;  40(5) e70
• 71 Gendrot C, Bacq Y, Brechot M C, Lansac J, Andres C. A second heterozygous MDR3 nonsense mutation associated with intrahepatic cholestasis of pregnancy.  J Med Genet. 2003;  40(3) e32
• 72 Savander M, Ropponen A, Avela K et al.. Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy.  Gut. 2003;  52(7) 1025-1029
• 73 Keitel V, Vogt C, Häussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy.  Gastroenterology. 2006;  131(2) 624-629
• 74 Wasmuth H E, Glantz A, Keppeler H et al.. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene.  Gut. 2007;  56(2) 265-270
• 75 Bacq Y, Gendrot C, Perrotin F et al.. ABCB4 gene mutations and single-nucleotide polymorphisms in women with intrahepatic cholestasis of pregnancy.  J Med Genet. 2009;  46(10) 711-715
• 76 Hardikar W, Kansal S, Oude Elferink R P, Angus P. Intrahepatic cholestasis of pregnancy: when should you look further?.  World J Gastroenterol. 2009;  15(9) 1126-1129
• 77 de Pagter A GF, van Berge Henegouwen G P, ten Bokkel Huinink J A, Brandt K H. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives?.  Gastroenterology. 1976;  71(2) 202-207
• 78 Brenard R, Geubel A P, Benhamou J P. Benign recurrent intrahepatic cholestasis. A report of 26 cases.  J Clin Gastroenterol. 1989;  11(5) 546-551
• 79 Mazzella G, Rizzo N, Azzaroli F et al.. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.  Hepatology. 2001;  33(3) 504-508
• 80 Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy.  Gastroenterology. 2005;  129(3) 894-901
• 81 Pauli-Magnus C, Meier P J. Hepatobiliary transporters and drug-induced cholestasis.  Hepatology. 2006;  44(4) 778-787
• 82 Lang C, Meier Y, Stieger B et al.. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury.  Pharmacogenet Genomics. 2007;  17(1) 47-60
• 83 Jacquemin E, Lykavieris P, Chaoui N, Hadchouel M, Bernard O. Transient neonatal cholestasis: origin and outcome.  J Pediatr. 1998;  133(4) 563-567
• 84 Bezerra J, Shneider B L. Genetic modifiers of cholestatic liver disease: an evolving field.  J Pediatr Gastroenterol Nutr. 2006;  42(1) 7-8
• 85 Ziol M, Barbu V, Rosmorduc O et al.. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults.  Gastroenterology. 2008;  135(1) 131-141
• 86 Gotthardt D, Runz H, Keitel V et al.. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults.  Hepatology. 2008;  48(4) 1157-1166
• 87 Hamosh A, Rosenstein B J, Cutting G R. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells.  Hum Mol Genet. 1992;  1(7) 542-544
• 88 Gottesman M M, Hrycyna C A, Schoenlein P V, Germann U A, Pastan I. Genetic analysis of the multidrug transporter.  Annu Rev Genet. 1995;  29 607-649
• 89 Beaudet L, Urbatsch I L, Gros P. Mutations in the nucleotide-binding sites of P-glycoprotein that affect substrate specificity modulate substrate-induced adenosine triphosphatase activity.  Biochemistry. 1998;  37(25) 9073-9082
• 90 Urbatsch I L, Beaudet L, Carrier I, Gros P. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites.  Biochemistry. 1998;  37(13) 4592-4602
• 91 Loo T W, Clarke D M. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein.  Biochemistry. 1994;  33(47) 14049-14057
• 92 Loo T W, Clarke D M. Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12.  J Biol Chem. 1997;  272(34) 20986-20989
• 93 Toh S, Wada M, Uchiumi T et al.. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome.  Am J Hum Genet. 1999;  64(3) 739-746
• 94 Riordan J R. Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein.  Am J Hum Genet. 1999;  64(6) 1499-1504
• 95 Meier Y, Pauli-Magnus C, Zanger U M et al.. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver.  Hepatology. 2006;  44(1) 62-74
• 96 Hoffmeyer S, Burk O, von Richter O et al.. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.  Proc Natl Acad Sci U S A. 2000;  97(7) 3473-3478
• 97 Forbes J R, Cox D W. Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant?.  Am J Hum Genet. 1998;  63(6) 1663-1674
• 98 Ortiz D, Arias I M. MDR3 mutations: a glimpse into Pandora's Box and the future of canalicular pathophysiology.  Gastroenterology. 2001;  120(6) 1549-1552
• 99 Houdayer C, Dehainault C, Mattler C et al.. Evaluation of in silico splice tools for decision-making in molecular diagnosis.  Hum Mutat. 2008;  29(7) 975-982
• 100 Keitel V, Burdelski M, Vojnisek Z, Schmitt L, Häussinger D, Kubitz R. De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis.  Hepatology. 2009;  50(2) 510-517
• 101 Jara P, Hierro L, Martínez-Fernández P et al.. Recurrence of bile salt export pump deficiency after liver transplantation.  N Engl J Med. 2009;  361(14) 1359-1367
• 102 Soubrane O, Gauthier F, DeVictor D et al.. Orthotopic liver transplantation for Byler disease.  Transplantation. 1990;  50(5) 804-806
• 103 Cutillo L, Najimi M, Smets F et al.. Safety of living-related liver transplantation for progressive familial intrahepatic cholestasis.  Pediatr Transplant. 2006;  10(5) 570-574